Alkermes Receives Refusal to File Letter From FDA for ALKS 5461 - Benzinga

Submitted by Anonymous (not verified) on Mon, 04/02/2018 - 12:41

Alkermes Receives Refusal to File Letter From FDA for ALKS 5461BenzingaDUBLIN, April 2, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that it received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily, oral ...